-
Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million
•
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire an 87.5% stake in US-based liquid embolic agent specialist BlackSwan Vascular Inc., for USD 37.5 million. This strategic move signifies Grand Pharma’s commitment to expanding its global presence in the medical device industry. BlackSwan Vascular…
-
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
-
Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct two clinical studies. One study will investigate the combination of its drug candidate BL-B01D1 with osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small…
-
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
•
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB…
-
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
-
Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has announced a strategic partnership with Qitan Tech, a Chengdu-based nanopore gene sequencer manufacturer. The collaboration aims to drive technology development, regulatory filings, localization, and industrialization of nanopore gene sequencers in the preimplantation genetic testing (PGT)…
-
Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its small-molecule HER2 inhibitor, pyrotinib. The drug is now approved for use in combination with Herceptin (trastuzumab) plus chemotherapy to treat recurrent or metastatic breast cancer…
-
Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
•
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a Phase I/II clinical study for its antibody-drug conjugate (ADC), XNW27011. The study will focus on locally advanced unresectable or metastatic malignant solid tumors expressing Claudin 18.2 (CLDN18.2).…
-
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
•
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Shire’s Firazyr (icatibant). This marks a significant milestone as the company becomes the first manufacturer to file for Drug…
-
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
-
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
-
Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up…
-
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
•
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment of USD 100 million in 2018, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RSS0343, intended to treat non-cystic fibrosis bronchiectasis (NCFB). Understanding Non-Cystic Fibrosis Bronchiectasis…
-
Siemens Healthineers and China Chest Pain Center Launch Smart Training Program
•
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center to launch the “Rising Star smart chest pain center standardized construction training program.” This initiative is designed to enhance the standardized construction of chest pain treatment processes and improve clinical intervention diagnosis and treatment capabilities.…
-
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of primary intracranial malignant tumors. TRPML1 Inhibitor’s Non-Clinical Study ResultsNon-clinical studies have demonstrated that the TRPML1 inhibitor, Y-1, can effectively inhibit…
-
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
•
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic diseases, has successfully raised tens of millions of renminbi in a Series B+ financing round. The funds will be allocated to the development and advancement of the company’s innovative pipelines and to support its robust…
-
Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report, recording RMB 21.275 billion (USD 3.08 billion) in revenues, marking a 17.87% year-on-year (YOY) decrease. Innovative drugs contributed RMB 8.116 billion (USD 1.77 billion) to the total revenues. The net profit attributable to the owners…
-
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has filed a 6-K with the US Securities and Exchange Commission and published clinical studies with the European Hematology Association (EHA) regarding its chimeric antigen receptor (CAR)-T therapies. The release…
-
HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs
•
China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen’s self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for…
-
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
•
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round co-led by CBC Group and the Abu Dhabi sovereign wealth fund Mubadala Investment Company, with participation from other unnamed institutional investors. The capital raised is intended to fund future acquisitions and deal-making focused on innovative…
